KEY FEATURES
| Full Name | Vascular Endothelial Growth Factor D |
|---|---|
| Synonym | FIGF; VEGF-D; C-Fos Induced Growth Factor |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 15.6-1000pg/mL |
| Sensitivity | 5.7pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human VEGFD in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human VEGFD. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human VEGFD and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human VEGFD, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human VEGFD. You can calculate the concentration of Human VEGFD in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human VEGFD ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 52.34 | 84.94 | 464.81 | 47.28 | 79.73 | 489.64 |
| Standard deviation | 2.97 | 4.6 | 18.55 | 2.54 | 4.71 | 24.19 |
| CV(%) | 5.67 | 5.41 | 3.99 | 5.38 | 5.91 | 4.94 |
RECOVERY
The recovery of Human VEGFD spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 88-102 | 94 |
| EDTA plasma (n=8) | 90-101 | 95 |
| Cell culture media (n=8) | 91-105 | 97 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human VEGFD in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with FIGF ELISA Kits
| FLT4 ELISA Kit | publications with FIGF and FLT4 |
| KDR ELISA Kit | publications with FIGF and KDR |
| FLT1 ELISA Kit | publications with FIGF and FLT1 |
| ALB ELISA Kit | publications with FIGF and ALB |
Pathways associated with FIGF ELISA Kit
| Cytokine-cytokine Receptor Interaction Pathway | Cytokine-cytokine Receptor Interaction Pathway |
| Focal Adhesion Pathway | Focal Adhesion Pathway |
| Hemostasis Pathway | Hemostasis Pathway |
| PI3K-Akt Signaling Pathway | PI3K-Akt Signaling Pathway |
| Pathways In Cancer | Pathways In Cancer |
| Platelet Activation, Signaling And Aggregation Pathway | Platelet Activation, Signaling And Aggregation Pathway |
Diseases associated with FIGF ELISA Kit
| Nervous System Diseases | publications with FIGF and Nervous System Diseases |
| Breast Neoplasms | publications with FIGF and Breast Neoplasms |
| Inflammation | publications with FIGF and Inflammation |
| Mammary Neoplasms, Animal | publications with FIGF and Mammary Neoplasms, Animal |
| Lung Neoplasms | publications with FIGF and Lung Neoplasms |
| Weight Gain | publications with FIGF and Weight Gain |
| Kidney Diseases | publications with FIGF and Kidney Diseases |
| Prenatal Exposure Delayed Effects | publications with FIGF and Prenatal Exposure Delayed Effects |
| Insulin Resistance | publications with FIGF and Insulin Resistance |
| Hyperglycemia | publications with FIGF and Hyperglycemia |
Organs/Tissues associated with FIGF ELISA Kit
| Lung | publications with FIGF and Lung |
| Kidney | publications with FIGF and Kidney |
| Muscle | publications with FIGF and Muscle |
| Heart | publications with FIGF and Heart |
| Liver | publications with FIGF and Liver |
| Intestine | publications with FIGF and Intestine |
| Spleen | publications with FIGF and Spleen |
| Uterus | publications with FIGF and Uterus |
| Mammary Gland | publications with FIGF and Mammary Gland |
| Brain | publications with FIGF and Brain |